Hepatitis C Board decisions

The Board remands the issues of service connection for hepatitis C, an initial increased rating in excess of 20 percent for osteoarthritis, left shoulder acromioclavicular joint, and total disability rating based on individual unemployability (TDIU) due to inadequate VA examinations.

The Board remands the matter for a new medical opinion addressing the etiology of the Veteran's hepatitis C, specifically regarding potential risk factors including air gun inoculations and IV drug use without sharing needles.

The appeal for service connection for prostate cancer, Hepatitis C, and non-Hodgkin's lymphoma was dismissed due to non-compliance with essential claims-processing rules.

The Board denied service connection for the veteran's claimed conditions, including hepatitis C, numbness of upper arms, psychiatric disorder, lung cancer, colon polyps, hemorrhoids, low back pain, and neck condition.

The Board dismissed the appellant's claims for earlier effective dates for service connection for spine cancer and hepatitis C as they were deemed to be 'freestanding' effective date claims, which are not allowed.

The Board granted readjudication of six service connection claims based on new and relevant evidence, including hearing testimony and a nexus statement from Dr. Townsend. All six claims were remanded for further development, including obtaining incomplete service treatment records, VA treatment records, private medical records, and adequate VA examinations and medical opinions.

The Board denied service connection for multiple conditions, including right hip disorder, genitourinary disorders, loss of sense of smell, and others, finding no evidence linking these conditions to the Veteran's military service or toxic exposure at Camp Lejeune.

The Board denied the Veteran's claim for service connection for hepatitis C, finding no evidence that the condition began during active service or is otherwise related to an in-service injury or disease.

The veteran's claim for service connection for hepatitis C was granted. The claim for vestibular disability was denied, and the dental condition claim was remanded.

The Board remanded the claim for service connection for GERD, including as secondary to service-connected hepatitis C, due to inadequate medical opinions. The Veteran's claim will be reconsidered with new evidence.

The appeal for service connection of hepatitis C is remanded because the medical opinion did not comply with the Board's directives. Another medical opinion is needed.

The Board granted service connection for hypertension and denied it for ischemic heart disease. Several other claims were remanded for further development.

The Board denied service connection for hepatitis C, right foot disability (metatarsalgia), and left knee disability. The evidence did not show these conditions are related to active service.

The Board has remanded the claims for service connection for cellulitis, a psychiatric disability, hepatitis C, thyroid disability, and colon polyps due to insufficient evidence or incomplete examinations.

The Board granted service connection for posttraumatic stress disorder (PTSD) and hepatitis C as secondary to the Veteran's service-connected PTSD associated drug use.

The veteran is granted an effective date of November 1, 2008 for a total disability rating based on individual unemployability due to service-connected disabilities.

The Veteran's claim for special monthly compensation (SMC) based on aid and attendance was granted, effective December 31, 2016.

The veteran's claims for service connection for several conditions were dismissed or denied. The veteran failed to appear for scheduled examinations, which led to the denial of increased ratings for lumbar strain and right ear hearing loss.

The Board denied the veteran's claims for earlier effective dates for service connection for hepatitis C, special monthly compensation (SMC), and Dependents' Educational Assistance (DEA).

The Veteran's claims for service connection for hepatitis C and related liver conditions, including cirrhosis and liver cancer, have been granted.